DiagnosisClinical DiagnosisDiagnostic criteria. The diagnosis of hyperkalemic periodic paralysis type 1 (hyperPP1) is based on the following findings:A history of at least two attacks of flaccid limb weakness (which may also include weakness of the muscles of the eyes, throat, and trunk)Hyperkalemia (serum potassium concentration >5 mmol/L) or an increase of serum potassium concentration of at least 1.5 mmol/L during an attack of weakness and/or onset/worsening of an attack as a result of oral potassium intakeNormal serum potassium concentration and muscle strength between attacksDisease manifestations before age 20 yearsAbsence of paramyotonia (i.e., muscle stiffness aggravated by cold and exercise)Absence of cardiac arrhythmia between attacksNormal psychomotor developmentTypically, at least one affected first-degree relativeExclusion of other hereditary forms of hyperkalemia (See Differential Diagnosis) and acquired forms of hyperkalemia (drug abuse, renal and adrenal dysfunction)Electromyogram (EMG). The diagnosis is strongly supported by the presence of myotonic signs in the EMG; however, approximately 50% of affected individuals with the most common mutation have no detectable electrical myotonia:During the attack, EMG demonstrates a reduced number of motor units or may be silent (no insertional or voluntary activity).In the intervals between attacks, EMG may reveal myotonic activity (bursts of action potentials with amplitude and frequency modulation), even though myotonic stiffness may not be clinically present.In some individuals, especially in those with permanent weakness, a myopathic pattern may be visible.TestingSerum potassium concentrationDuring an attack, the serum potassium concentration is elevated by 1.5-3 mmol/L, which is usually sufficient to surpass 5 mmol/L total concentration.
Note: At the end of an attack of weakness, elimination of potassium via the kidney and reuptake of potassium by the muscle can cause transient hypokalemia that may lead to the misdiagnosis of hypokalemic periodic paralysis.Even though the serum potassium concentration seldom reaches cardiotoxic levels, changes in the ECG (increased amplitude of T waves) may occur.Serum creatine kinase (CK) concentration. In the intervals between attacks, serum CK concentration is elevated (sometimes 5-10x the normal range) whereas serum sodium and potassium concentrations are normal.Provocative tests. In case of diagnostic uncertainty, i.e., in the absence of a measurement of ictal (during an attack) serum potassium concentration and negative molecular genetic studies, a provocative test can be employed to ensure the diagnosis. Systemic provocative tests carry the risk of inducing a severe attack; therefore, they must be performed by an experienced physician and a stand-by anesthetist, with close monitoring of the ECG and serum concentration of potassium:The classic provocative test consists of the administration of 2-10 g potassium under clinical surveillance with serum potassium concentration and strength measured at 20-minute intervals. Usually, an attack is induced within an hour and lasts approximately 30 to 60 minutes, accompanied by an increase in serum potassium concentration, similar to spontaneously occurring attacks of weakness. The test is contraindicated in individuals who already have hyperkalemia and in those individuals who do not have adequate renal or adrenal function.An alternative provocative test is exercise on a bicycle ergometer for 30 minutes to increase the heart rate to 120-160 beats/min, followed by absolute rest in bed. An affected individual's serum potassium concentration should rise during exercise, decline after exercise, and rise a second time 20 minutes after the conclusion of exercise.A local provocative test is measurement of evoked compound muscle action potentials (CMAP). They should have a greater-than-normal increase during two to five minutes of exercise followed by a progressive decline in amplitude that is greater than in normal controls and most rapid during the first 20 minutes after exercise. The decline is the more important parameter [Melamed-Frank & Marom 1999, Fournier et al 2004]. In the authors’ experience, the CMAP results are not specific for hyperPP or a given mutation.Muscle biopsy. Because no specific findings are observed on muscle biopsy and because the results do not influence therapeutic strategies or prognosis, a muscle biopsy is generally not recommended in individuals suspected of having hyperPP1. At onset of the occurrence of attacks of weakness, the muscle fibers do not show morphologic abnormalities even at the ultrastructural level. Further in the course of the disease, but independent of the severity of the attacks of weakness, proliferation, dilation, and degeneration of components of the T tubular system and the sarcoplasmic reticulum occur, leading to the formation of vacuoles resulting in a "vacuolar myopathy" [Jurkat-Rott et al 2002].Molecular Genetic TestingGene. HyperPP1 is caused by point mutations in SCN4A [Fontaine et al 1990], encoding the voltage-gated skeletal muscle sodium channel.Clinical testingTargeted mutation analysis. Molecular genetic testing for nine common mutations (See Table 1) detects a mutation in approximately 60% of individuals with hyperPP1, as defined by the clinical diagnostic criteria [Jurkat-Rott & Lehmann-Horn 2007].Sequence analysis. SCN4A sequence analysis may be performed to identify mutations in affected individuals who have tested negative for the nine common mutations.Sequence analysis of select exons. The exons sequenced vary by laboratory but may include exons 13, 14, 19, 22, 23, and 24.Table 1. Summary of Molecular Genetic Testing Used in Hyperkalemic Periodic Paralysis Type 1View in own windowGene SymbolTest MethodMutations Detected ^{1Mutation Detection Frequency by Mutation and Test Method 2Test AvailabilitySCN4ATargeted mutation analysis 3p.Leu689Ile<1%Clinicalp.Ile693Thr~15%p.Thr704Met~59%p.Ala1156Thr<1%p.Met1360Val<1%p.Met1370Val<1%p.Ile1495Phe<1%p.Met1592Val<25%p.[Phe1490Leu; Met1493Ile]<1%Sequence analysis of select exonsSequence variants 4,580% Sequence analysisSequence variants 4, targeted mutations and others80%1. See Table 3. Mutations detected may vary by laboratory.2. The ability of the test method used to detect a mutation that is present in the indicated gene3. Targeted mutation analysis refers to testing for specific common SCN4A mutation(s).4. Examples of mutations detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site mutations.5. Specific exons sequenced may vary by laboratory.Interpretation of test results. For issues to consider in interpretation of sequence analysis results, click here.Testing StrategyTo confirm/establish the diagnosis in a proband, the following tests are indicated:Serum potassium concentrations interictally and, if possible, during a paralytic attackECG recording for the exclusion of a long QT and ventricular arrhythmiasEMG recording (myotonic activity supports the diagnosis of hyperPP in contrast to HOKPP)Serum CK concentration (usually slightly increased)Molecular genetic testing of SCN4A and, if negative, KCNJ2 and CACNA1S. In contrast, sequencing of KCNE3 is not required [Jurkat-Rott & Lehmann-Horn 2004].In individuals who have atypical clinical features or lack an SCN4A mutation, provocative test, Holter recording, and muscle biopsyPredictive testing for at-risk asymptomatic family members to institute preventive measures prior to surgery requires prior identification of the disease-causing mutation in the family.Prenatal diagnosis and preimplantation genetic diagnosis (PGD) for at-risk pregnancies requires prior identification of the disease-causing mutation in the family.Genetically Related (Allelic) DisordersSeveral types of myotonia and periodic paralyses (PP) are caused by mutations in SCN4A.Potassium-aggravated myotonias. Individuals with potassium-aggravated myotonia develop severe stiffness following vigorous exercise or oral ingestion of potassium. The spectrum ranges from mild (myotonia fluctuans) to very severe (myotonia permanens):Myotonia fluctuans, the mildest form, in which the affected individuals either are not aware of muscle stiffness or may experience stiffness that tends to fluctuate from day to day [Ricker et al 1994]. After resting for several minutes, a single contraction may produce such severe stiffness (delayed myotonia) that the individual is unable to move for several hours. This sometimes painful, exercise-induced muscle cramping may be induced by or associated with hyperkalemia or other depolarizing agents [Heine et al 1993, Orrell et al 1998]. The stiffness subsides upon continued exercise (warm-up phenomenon).Acetazolamide-responsive myotonia, also known as atypical myotonia congenita [Ptácek et al 1994], in which muscle pain may be induced by exercise and the symptoms are alleviated by acetazolamideMyotonia permanens, a very severe form, in which continuous myotonic activity is noticeable on EMG. The continuous electrical myotonia leads to a generalized muscle hypertrophy (including face muscles) so severe that there has been confusion with Schwartz-Jampel syndrome [Lehmann-Horn et al 2004]. This condition is caused by a specific mutation in SCN4A [Lerche et al 1993].Paramyotonia congenita. The cardinal symptom of paramyotonia congenita is cold-induced muscle stiffness that increases with continued activity (i.e., paradoxical myotonia). Characteristic is the inability to reopen the eyes after several forceful closures in rapid succession. Paramyotonia is usually not induced or aggravated by potassium. In most families, the stiffness gives way to flaccid weakness or even to paralysis on intensive exercise and cooling:Families with p.Arg1448Ser, p.Arg1448Cys, p.Arg1448His, and p.Arg1448Pro substitutions also have attacks of generalized hyperkalemic periodic paralysis provoked by rest or ingestion of potassium lasting for an hour or less. In contrast, the cold-induced weakness usually lasts several hours even when the muscles are immediately rewarmed.In a Japanese family, the mutation p.Met1370Val resulted in paramyotonia in one family member and in hyperkalemic periodic paralysis in others [Okuda et al 2001].In the typical hyperPP1-causing mutations such as p.Thr704Met and p.Met1592Val, the signs of paramyotonia have been reported in single families [Kelly et al 1997, Kim et al 2001, Brancati et al 2003].Hypokalemic periodic paralysis type 2. Hypokalemic periodic paralysis (HOKPP) is characterized by episodic attacks of flaccid weakness associated with a drop in serum potassium concentration (hypokalemia). The changes in serum potassium concentration are opposite to those seen in hyperPP1, as is the response to certain provocative tests: oral administration of potassium relieves an attack provoked by a carbohydrate-rich meal. No myotonia is detectable in this disease. The recurrent attacks are of longer duration than in hyperPP1; myopathy and permanent weakness also occur [Jurkat-Rott et al 2000]. SCN4A substitution mutations at codon 672 (p.Arg672Ser, p.Arg672Gly, p.Arg672Cys, p.Arg672His) and p.Arg669His cause HOKPP2.Normokalemic periodic paralysis (see also Nomenclature). A type of periodic paralysis with normokalemic episodes of weakness reminiscent of both hyperPP and HOKPP has been reported: potassium sensitivity resembles hyperPP whereas all other features resemble HOKPP. This phenotype, named normokalemic periodic paralysis, is caused by SCN4A substitution mutations at codon 675 [Vicart et al 2004]. Codon 675 encodes an arginine in the voltage sensor of domain 2 of the sodium channel next to codons Arg669 and Arg672, which are responsible for HOKPP. It is unclear at present whether the term normokalemic periodic paralysis will continue to be used. Most of the patients in the authors’ cohort were hypokalemic during paralytic attacks.Congenital myasthenic syndrome is associated with fatigable generalized muscle weakness and recurrent attacks of respiratory and bulbar paralysis from birth. Congenital myasthenic syndrome is caused by an SCN4A mutation [Tsujino et al 2003].}

Natural HistoryThe attacks of flaccid muscle weakness associated with hyperkalemic periodic paralysis type 1 (hyperPP1) usually begin in the first decade of life and increase in frequency and severity over time. Potassium-rich food or rest after exercise may precipitate an attack [Lehmann-Horn et al 2004]. Also, a cold environment, emotional stress, glucocorticoids, and pregnancy provoke or worsen the attacks.A spontaneous attack commonly starts in the morning before breakfast, lasts for 15 minutes to an hour, and then passes. In some individuals, paresthesias, probably induced by the hyperkalemia, herald the weakness. During an attack of weakness, the muscle stretch reflexes are abnormally diminished or absent.Sustained mild exercise after a period of strenuous exercise may postpone or prevent the weakness in the muscle groups being exercised and improve the recovery of muscle force, while the resting muscles become weak.Usually, cardiac arrhythmia or respiratory insufficiency does not occur during the attacks.In approximately 50% of individuals with hyperPP1, mild myotonia (muscle stiffness) that does not impede voluntary movements is present between attacks. Myotonia is most readily observed in the facial, lingual, thenar, and finger extensor muscles; if present, it supports the diagnosis of hyperPP1 as opposed to other forms of familial periodic paralysis.Initially infrequent, the attacks increase in frequency and severity over time until approximately age 50 years, after which the frequency declines considerably. However, many older individuals develop a chronic progressive myopathy [Bradley et al 1990] with permanent weakness that may go unrecognized. The myopathy mainly affects the pelvic girdle and proximal and distal lower-limb muscles.

Genotype-Phenotype CorrelationsGiven the clinical variability within a single family (i.e., among individuals with the same mutation), mutation differences can be interpreted as causing a tendency to develop a feature, rather than actually causing a discrete feature (see Table 2).The most notable tendency is that individuals without interictal myotonia are much more prone to develop progressive myopathy and permanent weakness than individuals with myotonia. This becomes especially obvious in individuals with the p.Thr704Met mutation without myotonia, approximately half of whom develop permanent myopathy. Furthermore, some individuals with "normokalemic periodic paralysis" (a term no longer in use: see Nomenclature) have had this common mutation as well [Lehmann-Horn et al 1993].Table 2. Genotype-Phenotype Correlations in HyperPP1View in own windowSCN4A Mutation ^{1Special FeaturesFirst Reportp.Leu689IlePain resulting from muscle crampingBendahhou et al [2002]p.Ile693ThrCold-induced weaknessPlassart et al [1996]p.Thr704MetPermanent weakness, myopathyPtácek et al [1991]p.Ala1156ThrReduced penetranceMcClatchey et al [1992]p.Met1360ValReduced penetranceWagner et al [1997]p.Met1370ValParamyotonia in one family, hyperPP in othersOkuda et al [2001]p.Ile1495PheCramping pain, muscle atrophyBendahhou et al [1999]p.Met1592ValClassic clinical features with EMG myotoniaRojas et al [1991]p.[Phe1490Leu;
p.Met1493Ile]Malignant hyperthermia susceptibility 2Bendahhou et al [2000]1. See Table 3.2. The anesthesia-related events could have been exaggerated myotonic reactions as in several other individuals with gain-of-function sodium channel mutations [Klingler et al 2005].}

Differential DiagnosisIn addition to the allelic disorders described in Genetically Related Disorders, hereditary disorders with periodic paralysis or with hyperkalemia to consider when making the diagnosis of hyperkalemic periodic paralysis type 1 (hyperPP1) are discussed below. Adult onset of clinical manifestations points to other diagnoses such as the Andersen-Tawil syndrome or secondary acquired forms of hyperPP.HyperPP1, caused by mutations in SCN4A, accounts for approximately 60% to 70% of hyperPP; the other gene(s) causing hyperPP are unknown:At least one other locus, Xp27.3, has been mapped; the causative gene has not yet been identified [Ryan et al 1999]. Potassium levels are near normal but tend to vary within as well as among affected individuals. Episodes of severe muscle weakness, typically precipitated by febrile illness, affect the facial and extraocular musculature as well as the trunk and limbs, and resolve spontaneously over a period of weeks to months. Younger members of the family are normal between episodes but during relapses show generalized weakness, ptosis, and fluctuations in strength. In some cases, fatigability can be demonstrated and late-onset chronic weakness can occur.Both hyperPP and hypokalemic periodic paralysis (HOKPP) were reported to be caused by a mutation in another gene, KCNE3 (reference sequence NP_005463), resulting in a p.Arg83His substitution in a K+ channel beta subunit, MiRP2 [Abbott et al 2001]. Subsequent studies showed that p.Arg83His is a normal allelic variant with a prevalence of more than 1% in the general population, and mutations in KCNE3 do not cause periodic paralysis [Sternberg et al 2003, Jurkat-Rott & Lehmann-Horn 2004].Andersen-Tawil syndrome (potassium-sensitive cardiodysrhythmic type of periodic paralysis). Andersen-Tawil syndrome is characterized by the triad of episodic flaccid muscle weakness (i.e., periodic paralysis), ventricular arrhythmias and prolonged QT interval, and common anomalies such as low-set ears, ocular hypertelorism, small mandible, fifth-digit clinodactyly, syndactyly, short stature, and scoliosis. In the first or second decade, affected individuals present with either cardiac symptoms (palpitations and/or syncope) or weakness that occurs spontaneously following prolonged rest or rest after exertion. Mutations in the potassium channel gene KCNJ2 are causative [Plaster et al 2001]. Inheritance is autosomal dominant.Molecular genetic testing, electrocardiogram, and Holter recording obtained between attacks of weakness are very important for distinguishing between hyperPP1 and Andersen-Tawil syndrome.Hyperkalemic periodic paralysis with multiple sleep-onset REM periods. An individual with sporadic hyperPP and excessive daytime sleepiness with multiple sleep-onset REM periods has been reported. Symptoms were improved by a diuretic that decreased serum potassium concentration [Iranzo & Santamaria 1999]. Genetic analysis has not been performed.Hereditary disorders characterized by hyperkalemiaAdrenal insufficiency is characterized by hyperkalemia, hyponatremia, and hypoglycemia. Adrenal insufficiency in infancy may be caused by congenital adrenal hyperplasia (most commonly caused by 21-hydroxylase deficiency) and congenital adrenal hypoplasia including X-linked adrenal hypoplasia congenita. Adrenal cortical hypofunction (Addison disease) can be an autoimmune disorder with familial aggregation or combined with other endocrinopathies, particularly hypoparathyroidism. Addison disease also occurs in X-linked adrenoleukodystrophy.Recessive infantile hypoaldosteronism, another hyperkalemic disorder, leads to a rare form of salt wasting that may be life threatening during the first years of life. Recurrent dehydration and severe failure to thrive associated with mild hyponatremia and hyperkalemia are typical features. Laboratory tests reveal elevated plasma renin-to-serum aldosterone ratios and serum 18-hydroxycorticosterone to aldosterone ratios [Picco et al 1992].Pseudohypoaldosteronism type I is characterized by neonatal salt-wasting resistant to mineralocorticoids. The autosomal recessive form with symptoms persisting into adulthood is caused by loss-of-function mutations in one of the three homologous subunits forming the amiloride-sensitive epithelial sodium channel, ENaC [Chang et al 1996]. The channel is rate limiting for electrogenic sodium reabsorption, particularly in the distal part of the renal tubule. The autosomal dominant or sporadic form shows milder symptoms that remit with age. Truncation of the mineralocorticoid receptor has been identified in one family [Viemann et al 2001].Pseudohypoaldosteronism type II, also known as Gordon hyperkalemia-hypertension syndrome, is characterized by hypertension, increased renal salt reabsorption, and impaired potassium and hydrogen excretion resulting in hyperkalemia that may be improved by thiazide diuretics. Mutations have been identified in members of the WNK family of serine-threonine kinases expressed in the distal nephron, a kidney segment involved in salt, potassium, and pH homeostasis [Wilson et al 2001].Periodic paralysis secondary to acquired sustained hyperkalemia. This type of periodic paralysis can occur in any individual when the serum potassium concentration exceeds 7 mmol/L. Weakness can be accompanied by glove-and-stocking paresthesias. Hyperkalemia can cause cardiac arrhythmia, usually tachycardia, and typical ECG abnormalities (i.e., T-wave elevation, disappearance of P waves). Rest after exercise provokes weakness as in hyperPP1. The diagnosis is suggested by very high serum potassium concentration during the attack, persistent hyperkalemia between attacks, and the underlying disorder. Serum potassium concentrations are far higher than those in hyperPP1. The usual cause is chronic use of medications such as spironolactone, ACE inhibitors, trimethoprim, nonsteroidal anti-inflammatory drugs, and heparin. Myopathies associated with paroxysmal myoglobinuria (e.g., McArdle disease, carnitine palmitoyltransferase II transferase deficiency) can damage the kidney and thus also lead to potassium retention. Therapy of acquired sustained hyperkalemia involves restriction of dietary potassium intake and treating the underlying cause of the hyperkalemia.Note to clinicians: For a patient-specific ‘simultaneous consult’ related to this disorder, go to , an interactive diagnostic decision support software tool that provides differential diagnoses based on patient findings (registration or institutional access required).

ManagementEvaluations Following Initial DiagnosisTo establish the extent of disease in an individual diagnosed with hyperkalemic periodic paralysis type 1 (hyperPP1), the following baseline examinations are recommended:Neurologic status1H MRI (STIR) of proximal leg muscles to identify muscular water accumulation and fatty muscle degeneration [Weber et al 2006]. Edema should be extruded with long-term diuretics; evaluate by muscle strength measurement and MRI four weeks after start of treatment.Treatment of ManifestationsTreatment for hyperPP1 is symptomatic and not curative.Attacks can often be prevented or aborted by continuing mild exercise and/or oral ingestion of carbohydrates at the onset of weakness (e.g., 2.0 g glucose per kg body weight). Attacks occur more frequently on holidays and weekends when people rest in bed longer than usual; individuals are advised to rise early and have a full breakfast.In some individuals attacks can be aborted or attenuated by intravenously injected glucocorticoids or the inhalation of two puffs of 0.1 mg salbutamol.Calcium gluconate (0.5-2 g taken intravenously) may terminate attacks in some individuals [Lehmann-Horn et al 2004].Prevention of Primary ManifestationsPreventive therapy for individuals with hyperPP1 consists of frequent meals rich in carbohydrates and avoidance of potassium-rich medications and foods (e.g., fruits, fruit juices), fasting, strenuous work, and exposure to cold.It is often advisable to prevent hyperkalemic attacks of weakness by the continuous use of a thiazide diuretic or acetazolamide. The diuretics are used in modest dosages at intervals from twice daily to twice weekly. Thiazide diuretics are preferable because of the possible complications of acetazolamide therapy. The dosage should be kept as low as possible (e.g., 25 mg hydrochlorothiazide daily or every other day). In severe cases, 50 mg or 75 mg of hydrochlorothiazide should be taken daily very early in the morning. Individuals should be monitored so that the serum potassium concentration does not fall below 3.3 mmol/L or the serum sodium concentration below 135 mmol/L [Lehmann-Horn et al 2004].A Cochrane Database Systematic Review indicated that the largest study meeting the inclusion criteria suggested that dichlorphenamide* was effective in the prevention of episodic weakness and another study provided some evidence that acetazolamide may improve muscle strength. However, it was concluded that evidence was not sufficient to provide full guidelines for the treatment of persons with periodic paralysis [Sansone et al 2008]. * Dichlorphenamide is a carbonic anhydrase inhibitor like acetazolamide. It is currently used in a clinical trial and on the Italian market as Fenamide^®. Prevention of Secondary ComplicationsGeneral anesthesia. Opioids or depolarizing agents such as potassium, anticholinesterases, and succinylcholine can aggravate a myotonic reaction and induce masseter spasms and stiffness of respiratory muscles. Intubation and mechanical ventilation may be impaired. Also, alterations of serum osmolarity, pH, and hypothermia-induced muscle shivering and mechanical stimuli can exacerbate the myotonic reaction. An induction sequence incorporating inhalation of oxygen, cricoid pressure, thiamyal or thiopental, and two times the ED95 dose of an intermediate or short-action non-depolarizing muscle relaxant, followed by intubation, is a reasonable approach to securing the airway in persons with myotonia. Alternatively, inhalational induction may be a possibility for hyperkalemic paralysis and is well tolerated in patients undergoing elective surgery. Following administration of general anesthesia, the patient may develop respiratory distress in the recovery room resulting from weakness of respiratory muscles in addition to generalized weakness lasting for hours. The weakness is aggravated by drugs that depress respiration and by the hypothermia induced by anesthesia. To prevent such attacks, glucose should be infused, a normal body temperature maintained, and serum potassium kept at low level [Klingler et al 2005, Mackenzie et al 2006, Jurkat-Rott & Lehmann-Horn 2007, Barker 2010].Note: Because the generalized muscle spasms associated with such attacks may lead to an increase in body temperature, individuals with hyperPP1 have been considered to be susceptible to malignant hyperthermia. Most likely, anesthesia-related complications suggestive of a malignant hyperthermia crisis result from severe myotonic reactions [Lehmann-Horn et al 2004, Klingler et al 2005].SurveillanceThe frequency of consultations needs to be adapted to the individual's clinical features and the response to preventive treatment. Neurologic examination with attention to muscle strength in the legs should be performed, in order to detect permanent weakness. Permanent weakness requires continuous medication and MRI of the leg muscles once every one to three years. During treatment, serum potassium concentration should be measured twice per year to avoid severe diuretic-induced hypokalemia. The value should be between 3.0 and 3.5 mmol/L.Agents/Circumstances to AvoidSee Prevention of Secondary ComplicationsEvaluation of Relatives at RiskIt is appropriate to test asymptomatic at-risk family members for the disease-causing mutation identified in an affected relative in order to institute preventive measures prior to surgery.See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.Pregnancy Management Pregnancy can improve or worsen periodic paralysis in the first trimester [Author, personal observation]. One report describes marked improvement [Finsterer 2009]. Glucose taken orally at the beginning of an episode of weakness may reduce and shorten the attack. If preventive medication is needed, beta-sympathomimetic drugs such as albuterol can be used for both tocolysis as well as during the entire pregnancy because of the absence of teratogeneity. Therapies Under InvestigationSearch ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.OtherWhether the spontaneous attacks of weakness usually associated with hyperPP1 are influenced by mexiletine (the drug of choice for several allelic disorders) is unknown.No data concerning the influence of therapeutic drugs on the development of the myopathy are available.Cation exchangers are less beneficial than diuretics in treating hyperPP1 because they result in more severe side effects.

Molecular GeneticsInformation in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.Table A. Hyperkalemic Periodic Paralysis Type 1: Genes and DatabasesView in own windowGene SymbolChromosomal LocusProtein NameLocus SpecificHGMDSCN4A17q23​.3Sodium channel protein type 4 subunit alpha Sodium channel, voltage-gated, type IV, alpha subunit (SCN4A) @ LOVDSCN4AData are compiled from the following standard references: gene symbol from HGNC; chromosomal locus, locus name, critical region, complementation group from OMIM; protein name from UniProt. For a description of databases (Locus Specific, HGMD) to which links are provided, click here.Table B. OMIM Entries for Hyperkalemic Periodic Paralysis Type 1 (View All in OMIM) View in own window 170500HYPERKALEMIC PERIODIC PARALYSIS; HYPP 603967SODIUM CHANNEL, VOLTAGE-GATED, TYPE IV, ALPHA SUBUNIT; SCN4AMolecular Genetic PathogenesisHyperkalemic periodic paralysis type 1(hyperPP1)-causing mutations are situated at several disseminated, intracellularly faced positions potentially involved in the formation of the inactivation apparatus [Lehmann-Horn & Jurkat-Rott 1999]. Therefore, they lead to incomplete or slowed fast inactivation and a pathologically increased sodium current; the result is an increased tendency of the muscle fibers to depolarize.The degree of depolarization determines the clinical symptoms: slight depolarizations near the sodium channel threshold result in repetitive muscle action potentials (→ hyperexcitability = myotonic bursts in the EMG or clinically obvious myotonia); stronger depolarizations beyond the threshold lead to sodium channel inactivation and abolition of action potentials (→ reduced excitability resulting in muscle weakness) [Lehmann-Horn et al 1987]. The myotonia and the paralysis are thus caused by the same mechanism. The dominance of the mutation results from the fact that the mutation is decisive for excitability; i.e., it produces a so-called dominant gain of function. Potassium has no direct effect on the mutant channel but triggers an attack as a result of membrane depolarization that opens the sodium channels [Wagner et al 1997]. Whereas the normal channels properly inactivate, the mutant channels do not.Usually, a sodium current caused by incomplete fast inactivation should be terminated by slow channel inactivation. However, several hyperPP1-causing mutations also impair slow inactivation [Cummins & Sigworth 1996]. Although not essential for the occurrence of a paralytic attack, this incomplete slow inactivation presumably stabilizes the persistence of the sodium current, making the depolarization of the muscle fibers long enough to be clinically obvious. Several hyperPP-causing mutations are situated in the intracellular S4-S5 loops of the channel that act in a cooperative manner for proper fast inactivation and, dependent on the domain, are important for activation and deactivation [Popa et al 2004], whereas voltage sensor mutations mainly affect channel deactivation [Groome et al 2007].Normal allelic variants. SCN4A contains 24 exons. See Table 3, Normal allelic variants.Pathologic allelic variants. See Molecular Genetic Testing and Table 3, Pathologic allelic variants.Table 3. Selected SCN4A Allelic VariantsView in own windowClass of Variant AlleleDNA Nucleotide ChangeProtein Amino Acid ChangeReference Sequences ReferenceNormalc.737C>Tp.Ser246LeuNM_000334​.4
NP_000325​.4Tsujino et al [2003]c.968C>Tp.Thr323MetWu et al [2005]c.2341G>Ap.Val781IleGreen et al [1997]c.2717G>Cp.Ser906ThrKuzmenkin et al [2003]Pathologicc.2065C>Ap.Leu689IleBendahhou et al [2002]c.2078T>Cp.Ile693ThrPlassart et al [1996]c.2111C>Tp.Thr704Met Ptácek et al [1991]c.3466G>Ap.Ala1156Thr McClatchey et al [1992]c.4078A>Gp.Met1360Val Wagner et al [1997]c.4108A>Gp.Met1370ValOkuda et al [2001]c.4483A>Tp.Ile1495Phe Bendahhou et al [1999]c.4774A>Gp.Met1592Val Rojas et al [1991]c.[4468T>C; 4479G>A] ^{1p.[Phe1490Leu; Met1493Ile] 1Bendahhou et al [2000]See Quick Reference for an explanation of nomenclature. GeneReviews follows the standard naming conventions of the Human Genome Variation Society (www​.hgvs.org).1. Designates two variants in one alleleNormal gene product. The α subunit of the voltage-gated sodium channel of skeletal muscle comprises 1836 amino acids. The sodium channel of skeletal muscle is decisive for generating the so-called action potential, the signal by which excitation spreads over the muscle fiber in order to initiate a uniform contraction response [Lehmann-Horn & Jurkat-Rott 1999]. The main sodium channel subunit (the so-called α subunit) is mutated in hyperPP1. It is arranged as four homologous domains around a central ion-conducting pore. The α subunit determines the main characteristics of the sodium channel, conveying the properties of ion selectivity, voltage sensitivity, pharmacology, and binding characteristics for endogenous and exogenous ligands. The accessory β subunit has one transmembrane segment and binds to the α subunit with an extracellular immunoglobulin-like fold with a stoichiometry of 1:1. It influences channel expression, trafficking, and gating characteristics.The voltage-sensitive sodium channel has one open and at least two closed states: one from which the channel can be directly activated (the resting state) and one from which it cannot (the inactivated state) [Lehmann-Horn & Jurkat-Rott 1999]. This implies that at least two gates regulate the opening of the pore, an activation and an inactivation gate, both of which are usually mediated by the α subunit. In addition to the inactivated state produced by depolarizations of short duration, another inactivated state, the so-called slow inactivated state, has been described. It is elicited by long-lasting depolarizations [Ruff 1996]. Recovery from this state requires several seconds, in contrast to recovery from the fast inactivated state, which takes only a few milliseconds.Abnormal gene product. It is not known which parts of the channel protein are involved in generating the slow inactivated state, but functional studies of the mutations suggest that regions mutated in hyperPP1 are of importance. Because no long-lasting depolarizations physiologically exist (except in the diseased state), changes in the slow inactivated state may be associated with frequency modulation of the early postsynaptic potential of the neuromuscular endplate. Research has therefore included studies of high frequency-induced changes of inactivation [Richmond et al 1997].}